Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Glucagon (native, Prandial Infusion)

MARKETED

glucagon (GCGR agonist, physiology)

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Glucagon (native, Prandial Infusion) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Glucagon (native, Prandial Infusion) MARKETED
Appetite and food intake Decrease
Moderate evidence

In normal-weight men, intravenous pancreatic glucagon (~3 ng/kg/min, from 5 min before lunch) significantly reduced test-meal size without detectable side effects; a...

Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V, Am J Physiol 1992;262(6 Pt 2):R975-980 Source
Full findingIn normal-weight men, intravenous pancreatic glucagon (~3 ng/kg/min, from 5 min before lunch) significantly reduced test-meal size without detectable side effects; a lower dose (~1.5 ng/kg/min) had no effect, and glucagon+CCK-8 produced an infra-additive intake reduction. Canonical human glucagon-satiety datum.
PopulationNormal-weight young men (small n)
Fundingacademic-NIH/NIDDK
Scope limitsconference/abstract-level
Comparatorssaline; CCK-8